Illumina Announces HumanHap550+ and iSelect Infinium(TM) Genotyping Products; Flexible Offering Enables Design of Custom Array Content to Analyze up to 670,000 SNPs or 12 Samples on a Single BeadChip.SAN DIEGO -- Illumina, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :ILMN) announced today the immediate availability of two new Infinium genotyping products that provide an unprecedented degree of customization for customers performing whole-genome and focused-content SNP SNP Scottish National Party Noun 1. SNP - (genetics) genetic variation in a DNA sequence that occurs when a single nucleotide in a genome is altered; SNPs are usually considered to be point mutations that have been evolutionarily (single nucleotide polymorphism Noun 1. single nucleotide polymorphism - (genetics) genetic variation in a DNA sequence that occurs when a single nucleotide in a genome is altered; SNPs are usually considered to be point mutations that have been evolutionarily successful enough to recur in a ) genotyping. The new HumanHap550+ product allows customers to add up to 120,000 custom SNP markers to supplement the standard content provided on the existing HumanHap550 BeadChip, yielding up to 670,000 markers for association studies. For focused-content applications, the new iSelect Infinium product allows customers to create a custom array of up to 60,000 SNP markers per sample with 12 samples per chip. The multi-sample offering will typically be used by researchers who have already performed whole-genome genotyping and/or have narrowed down SNPs of interest to a large, yet focused set of markers relevant to the particular disease they are studying. Illumina is offering custom Infinium genotyping solutions as either a product or a service. The Company also provides a powerful bioinformatics tool that enables in silico SNP design and screening prior to probe synthesis. "These new products highlight the flexibility of the BeadChip format," stated Jay Flatley, Illumina President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . "The multi-stripe configuration and versatile gasketing technology developed as part of the BeadChip program allow for rapid production of customer-tailored products, enabling researchers to add custom content to our industry leading HumanHap550 or create fully custom multi-sample chips." Illumina also announced today a custom Infinium services agreement with Johnson & Johnson Pharmaceutical Development, L.L.C. -- the first such agreement for custom, multi-sample Infinium genotyping. For more information about custom Infinium genotyping or about other high-performance microarray solutions for genotyping and gene expression studies, contact Illumina's Customer Solutions Department at +1 858 202.4566 or e-mail info@illumina.com. About Illumina Illumina (www.illumina.com) develops and markets next-generation tools for the large-scale analysis of genetic variation and function. The Company's proprietary BeadArray technology -- used in leading genomics centers around the world -- provides the throughput, cost effectiveness and flexibility necessary to enable researchers in the life sciences and pharmaceutical industries to perform the billions of tests necessary to extract medically valuable information from advances in genomics and proteomics. This information will help pave the way to personalized medicine by correlating genetic variation and gene function with particular disease states, enhancing drug discovery, allowing diseases to be detected earlier and more specifically, and permitting better choices of drugs for individual patients. "Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: this release may contain forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are the costs and outcome of Illumina's litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. with Affymetrix, the Company's ability to scale and integrate CyVera technology, the ability to further scale oligo synthesis output and technology to satisfy market demand deriving from the Company's collaboration with Invitrogen, Illumina's ability to further develop and commercialize its BeadArray technologies and to deploy new gene expression and genotyping products and applications for its platform technology, to manufacture robust Sentrix(R) arrays -- including HumanHap BeadChips -- and Oligator(R) oligonucleotides, and other factors detailed in the Company's filings with the Securities and Exchange Commission including its recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. Illumina disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. Note on Infinium and GoldenGate Assays The Infinium Assay is infinitely multiplexible and its scalability is limited only by the number of features on the array itself (the densest Sentrix BeadChip contains over 12 million features). Following single-tube, whole-genome amplification (no PCR PCR polymerase chain reaction. PCR abbr. polymerase chain reaction Polymerase chain reaction (PCR) or ligation ligation /li·ga·tion/ (li-ga´shun) the application of a ligature. tubal ligation sterilization of the female by constricting, severing, or crushing the uterine tubes. steps), samples are hybridized to 50-mer bead-based probes. After a labeled extension step, the BeadChip is imaged on Illumina's BeadArray Reader, and then analyzed. Call rates routinely exceed 99%, with reproducibility and accuracy approaching 100% and HapMap concordance concordance /con·cor·dance/ (-kord´ins) in genetics, the occurrence of a given trait in both members of a twin pair.concor´dant con·cor·dance n. above 99.7%. The GoldenGate assay uses allele-specific primer extension and ligation reactions, following by priming, PCR amplification, and hybridization hybridization /hy·brid·iza·tion/ (hi?brid-i-za´shun) 1. crossbreeding; the act or process of producing hybrids. 2. molecular hybridization 3. to universal oligos on Sentrix arrays. In the collaborative first phase of the International HapMap Project The International HapMap Project is an organization whose goal is to develop a haplotype map of the human genome (the HapMap), which will describe the common patterns of human genetic variation. , more than 65% of the SNPs were genotyped and mapped using Illumina's GoldenGate assay. Additional Assay Reference Whole-Genome Genotyping with the Single-Base Extension Assay, Frank J. Steemers, Weihua Chang, Grace Lee, David Barker, Richard Shen Shen, in the Bible, place, perhaps close to Bethel, near which Samuel set up the stone Ebenezer. and Kevin Gunderson, Nature Methods, Vol. 3, No. 1, January 2006. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion